CRT 2026

Panel Discussion | Update of Heart Failure Management

Moderator(s)

• 

  Jonathan Grinstein, MD

  Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation Physician
  University of Chicago
  MedStar Washington Hospital Center
  Bethesda, MD, United States

  Disclosure information not submitted.
• 

  Richa Gupta, MD

  Assistant Professor of Medicine, Advanced Heart Failure and Transplant Cardiology
  MedStar Health

  Disclosure information not submitted.
• PL

  Phillip H. Lam, MD

  Advanced Heart Failure Cardiologist
  MedStar Health

  Disclosure information not submitted.

Panel Discussant(s)

• 

  William T. Abraham, MD

  Professor of Medicine
  The Ohio State University
  Columbus, Ohio, United States

  Disclosure(s): Abbott: Consulting Fees (e.g., advisory boards) (Ongoing); AquaPass: Consulting Fees (e.g., advisory boards) (Ongoing); Bioventrix: Consulting Fees (e.g., advisory boards) (Ongoing); Cardiac Dimensions: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing); Cordio Medical: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Impulse Dynamics: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Innoventric: Consulting Fees (e.g., advisory boards) (Ongoing); JNJ V-Wave: Consulting Fees (e.g., advisory boards) (Ongoing); SCPharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, October 31, 2025), Stock-publicly held company (excluding mutual/index funds) (Terminated, October 31, 2025); Sensible Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medtech: Consulting Fees (e.g., advisory boards) (Ongoing); WhiteSwell: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll Respicardia: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Dan Haberman, MD

  Consultant Cardiologist
  MedStar Washington Hospital Center
  Tel aviv, Israel

  Disclosure information not submitted.
• 

  M. Reza Movahed, Prof.

  Clinical Professor of Medicine
  University of Arizona, Tucson and Phoenix
  Tucson, Arizona, United States

  Disclosure(s): No financial relationships to disclose
• 

  Matthew Sherwood, MD, MHS

  System Director of Interventional Cardiology, Director of Structural Heart Program
  Inova Schar Heart and Vascular Institute, Virginia, United States

  Disclosure information not submitted.
• 

  Gregg W. Stone, MD, FACC, MSCAI

  Physician
  Mount Sinai
  New York, New York, United States

  Disclosure(s): Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter, Vascentis: Stock-privately held company (Ongoing); Cardiac Success, Occlutech, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio: Consulting Fees (e.g., advisory boards) (Terminated); Colibri, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Ancora, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Bioventrix, MedHub, Biotyx Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Pulnovo, V-wave and PCORI via Weill Cornell Medical Center.: Grant/Research Support (Ongoing)
• 

  James Udelson, MD

  Chief, Division of Cardiology
  Tufts Medical Center
  Boston, Massachusetts, United States

  Disclosure(s): Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)